CellCentric

Biotechnology · Cambridge, United Kingdom · Founded 2003 · Privately Held (backing)

Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. CellCentric is based in Cambridge, United Kingdom and was founded in 2003. It is valued at about $382 million as of Oct 2026, set by institutional fund marks. It has raised $281 million across 2 recorded rounds; the latest was an $116 million Series C in Apr 2025.

PMV mark · valuation
$382.5M
Oct 2026
Priced at
its later-stage round
Apr 2025
Total raised
$280.5M
Last round
Later Stage VC (Series C)
Apr 2025

Who backs CellCentric?

20 investors
InvestorType
Innovate UKOther
RA Capital ManagementAsset manager
5Y CapitalOther
Future Planet CapitalVenture capital
Cambridge Enterprise VenturesVenture capital
Morningside GroupVenture capital
UK Innovation & Science Seed FundVenture capital
ForbionVenture capital
NestaOther
Takeda VenturesVenture capital
+ 10 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

CellCentric investors

20 investors are on record for CellCentric, including Innovate UK, RA Capital Management, 5Y Capital and Future Planet Capital. By type, the record holds 8 venture capital firms and 1 asset manager. The Series C in Apr 2025 drew 3 investors.

Free account
More of CellCentric with a free account
  • ·The complete investor list: 20 names
  • ·Watch CellCentric: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 20 firms already write checks for companies like CellCentric in biotechnology. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View